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PHARMACOTHERAPEUTIC STUDY OF ANTIRETROVIRAL
THERAPY FOR HIV/AIDS PATIENTS AT THE FEDERAL
MEDICAL CENTRE, OWO, ONDO STATE, NIGERIA
ABSTRACT
A 6-12 months retrospective study is made of HAART utilization in cases of HIV/AIDS
patients at Federal Medical Centre, Owo, Nigeria. The objective to evaluate the rational
pharmacotherapeutic approach to the management of the retroviral disease. Sixty two (62)
antiretroviral drug-naive HIV/AIDS patients, which comprise of (19) 30.65% males with a
mean age of 37.15±8.55 years and (43) 69.35% females with a mean age of 35.68±9.75 years
case files are reviewed. The data used for this study was extracted from the clinical records
of the Hospital. Sixty six percent of the patients are at World Health Organization (WHO)
clinical stage III or IV of the HIV disease at initiation of HAART and 35.70% of patients have
baseline CD4 cell count ≤50 cells/µL. Stavudine/Lamivudine/Nevirapine is used as HAART
first line regimen in 87.10% of the patients while 12.90% are prescribed
Stavudine/Lamivudine/Efavirenz due to underlying TB infection. Three (3) patients switched
their initial regimen while a patient had her regimen discontinued because of drug adverse
effects. Evaluation of 35 patients for therapeutic response after a mean period of 9.07 months
shows that, in 82.86% of patients, mean CD4 cell count increased from 96.70 ± 67.90
cells/µL (median 104 cells/µL) at baseline to 267.60 ± 141 cells/µL (median 267 cells/µL).
After a mean period of 9.07 months of HAART, there is a significant difference in the change
in CD4 count among male and female patients there is no significant correlation between age
and change in patients’ CD4 count and within female patients but there is a significant
positive correlation between age and change in CD4 count within male patients. It is
therefore concluded that rational use of HAART in patients with retroviral disease will lead
to significant improvement in most patients’ immunological status and invariably quality of
life.
Keywords: Pharmacotherapeutics, HAART, HIV/AIDS, CD4 Count
INTRODUCTION
Acquired Immune Deficiency Syndrome or Acquired Immunodeficiency Syndrome (AIDS)
is a disease of the human immune system caused by the human immunodeficiency virus
(HIV) (Weiss, 1993; Sepkowitz, 2001). HIV causes AIDS by depleting CD4 T helper
lymphocyte. This weakens the immune system and allows opportunistic infections. T
lymphocytes are essential to the immune response and without them; the body cannot fight
infections or kill cancerous cells.
The CD4 count serves as the major clinical indicator of immunodeficiency in patients who
have HIV infection. It is the most important factor in deciding whether to initiate
antiretroviral therapy and opportunistic infection prophylaxis, and it is the strongest predictor
of subsequent disease progression and survival according to clinical trials and cohort studies
(Mellors et al, 1997; Egger et al, 2002).
Although AIDS was discovered in 1981 and HIV identified in 1983, it was not until 1985
that the first two HIV cases were identified in Nigeria and were reported at an international
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AIDS Conference in 1986 (Adeyi et al, 2006). By the end of 2008, the United Nations Joint
Programme on HIV/AIDS (UNAIDS) report on Nigeria estimates that around 3.1 percent of
adults between ages 15-49 are living with HIV/AIDS (UNAIDS, 2008).
The initial strategy of health experts as regards combating the HIV/AIDS scourge was to
focus on reducing the incidence of opportunistic infections that were shown to cause high
morbidity and mortality rather than inhibiting the growth of the virus (Fee & Krieger, 1993).
However, further studies on the pathogenesis of the disease as well as genetic basis of
resistance yielded positive result in 1987 with the registration of zidovudine as the first
antiretroviral agent by United States Food and Drug Administration (FDA) (Young, 1988).
Since that time, studies into the area of HIV therapeutics has been growing (Burton, 2006).
Antiretroviral drugs which are used for the treatment of HIV infection, essentially act by
blocking the action of enzymes that are important for replication and functioning of the HIV
(Palmisano & Vella, 2011).
The primary goals driving the decision to initiate antiretroviral therapy are to reduce HIVrelated morbidity and prolong survival, improve quality of life, restore and preserve
immunologic function, maximally and durably suppress viral load and prevent vertical HIV
transmission (DHHS Panel on Antiretroviral Guidelines, 2008).
In resource limited setting, initiation of antiretroviral therapy in adults and adolescents is
dependent on WHO clinical staging and CD4 count (WHO, 1990). Thus:
The WHO staging system of HIV/AIDS is as follows;
Stage I:

HIV Infection is asymptomatic, generalized lymphadenopathy.

Stage ii:

Weight loss less than 10% of bodyweight, fungal nail infection, herpes zoster,
recurrent upper respiratory tract infections (URTIs)

Stage iii:

Weight Loss greater than 10%, unexplained chronic diarrhoea for longer than
one month or fever, oral candidiasis/hairy leukoplakia, pulmonary TB, severe
bacterial infections.

Stage IV:

AIDS

defining

illness:

e.g.

HIV

wasting

syndrome,

PCP,

brain

toxoplasmosis’, candida oesophagitis, extra- pulmonary TB, CMV retinitis,
Kaposi Sarcoma, non – Hodgkin’s lymphoma.

Performance score 4:

bedridden greater than 50% of the day during the last month.
Nigeria’s national guideline endorses the WHO recommendations for initiating antiretroviral
therapy (ART) (FMoHN, 2005).
ART should be initiated in the following categories of patients.
If CD4 testing is available:
•

WHO stage IV disease irrespective of CD4 cell count;
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•

WHO stage III disease with CD4 count <350/mm3;

•

WHO stage I or II disease with CD4 cell count <200/mm3.

(Note: CD4 cell count <200/mm3 is believed to be associated with a state of
immunosuppression)
If CD4 testing is unavailable,
•

WHO stage IV disease irrespective of total lymphocyte count (TLC).

•

WHO stage III disease irrespective of TLC.

•

WHO stage II disease with a TLC ≤1200/mm3

In parallel with the discovery of ARVs has been a rapid evolution of different strategies for
optimizing their use (Detel et al, 1998). Current treatment for HIV infection consists of
HAART. This has been highly beneficial to many HIV-infected individuals since its
introduction in 1996 when the protease inhibitor-based HAART initially became available
(Beck et al, 2004; Murphy et al, 2001). Current optimal HAART options consist of
combinations (or “cocktails”) consisting of at least three drugs belonging to at least two types
or “classes” of antiretroviral agents (DHHS Panel on Antiretroviral Guidelines, 2008).
Typical regimens consist of two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) plus
either a Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or a Protease Inhibitor
(PIs) (DHHS Panel on Antiretroviral Guidelines, 2008).
While there are many effective HAART regimens that are used to treat HIV/AIDS, the initial
strategy must be based on proven potency, ease of administration, potential drug toxicities,
pharmacokinetics, expense and availability.
In Nigeria, the initial choice of dual NRTIs is typically limited to one or two options:
stavudine (but currently stavudine is gradually being replaced with tenofovir because of
peripheral neuropathy) plus lamivudine or zidovudine plus lamivudine (FMoHN, 2005). Both
are said to be effective but their side effect profiles are different. In addition to dual
nucleoside reverse transcriptase inhibitors, the third drug of a HAART regimen is a critical
choice (Squires et al, 2004; Staszewski et al, 1999). The most common third drug added to a
HAART regimen is a non-nucleoside reverse transcriptase inhibitor, either nevirapine or
efavirenz (F van Leth et al, 2004). An effective alternative to the non-nucleoside approach is
the addition of a protease inhibitor as the third drug in a HAART regimen. PIs based HAART
are only used as second line regimens in Nigeria (FMoHN, 2005).
The most effective and practical protease inhibitors to be considered for second line therapy
include lopinavir/ritonavir (Kaletra®), indinavir with or without ritonavir, and atazanavir
with or without ritonavir (WHO, 2006).
A lot of challenges are being encountered by both patients and care providers in achieving the
3

goals of therapy. This is due to the fact that HIV/AIDS patients on antiretroviral drugs most
often take other medications to treat either opportunistic infections or co morbidities
(Antoniou & Lin-in Tseng, 2002). This condition which is referred to as poly pharmacy gives
room for potential drug-drug interactions which may modify the expected therapeutic
outcomes (Piscitelli & Gallicano, 2001). Another impediment to the realization of full
benefits of HAART is patients’ non adherence usually resulting from drug adverse effects
(O’Brien et al., 2003). Therefore, HAART regimen must be tailored towards individual
patient needs if adequate therapeutic response is to be achieved at the end of therapy.
In order to tackle the burden of HIV/AIDS in Nigeria, the Federal government in
collaborations with International Donor Agencies started distributing free antiretroviral drugs
to patients since 1996 in treatment centres (WHO, UNAIDS and UNICEF, 2008). However
little is known about therapeutic endpoints of the drug intervention. The aim of this study
therefore, was to determine the appropriateness or otherwise of the current treatment
strategies in restoring immunological functions of HIV/AIDS patients among other goals of
ART. It is believed that such evaluation would be useful because, it will either reinforced or
call for a review of the current strategies.

Materials and Methods
A 6 to 12 month retrospective cohort study of sixty two (62) antiretroviral drug-naive patients
who attended Federal Medical Centre, Owo HIV/AIDS clinic between the periods of June
2006 to May 2007 and were offered HAART. The study was approved by Federal Medical
Centre Owo, Ethical Review Committee (ERC). To be selected for the study, the patient had
to be 13 years of age or older and completely antiretroviral drug-naive at the start of first-line
HAART. The patient must have been on HAART for at least 6 months by May 2007. Data
for patients were collected retrospectively using patient case files obtained from the Medical
Records Department of the health Institution. The files contain information on patient
characteristics (e.g. gender, age and weight), tests performed at initiation (Baseline) of ART
and during the course of ART (e.g. liver function test (LFT), CD4 cell count, full blood
count and drug resistance testing), patient clinical status at the time of initiation of therapy
(e.g. WHO clinical stage, concurrent disease and physical assessment), detailed treatment
data (e.g. use of antiretrovirals, prophylactic medications against opportunistic infections,
concurrent medications, dose frequency, start and stop dates and reasons for treatment
change) and adverse effects data. The analysis of the collated data was carried out with the
use of both descriptive and quantitative techniques. The descriptive technique involves the
use of frequency table and bar chart, while the quantitative technique involved the use of non
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parametric statistics Mann-Whitney U-test and Spearman Rank Correlation test (Bamgboye,
2006).

RESULTS
Patient categorization based on 2006 WHO clinical staging system
Sixty percent (60%) of the patients studied were at stage III of the WHO clinical stage of
retroviral disease (mean CD4 count 87 cells/µL), 12.90% at stage I (mean CD4 count 114.88
cells/µL), 20.97% at stage II (mean CD4 count 94.92 cells/µL) and 6.45% of patients were at
stage IV (mean CD4 count 60 cells/µL) of the disease (Figure 1).

PATIENT CD4 COUNT AT BASELINE.
All the patients performed baseline CD4 count at the beginning of study, except 6 patients
who had total lymphocyte count (TLC) performed due to non-availability of CD4 count
determining machine at the time of entry into treatment (The machine was later acquired in
November, 2006). The TLC values were <1200 cells/µL. The analysis of the patients baseline
CD4 cell count showed a range of 4-278 cells/µL (mean 92 ± 61 cells/µL). About thirty five
percent (35.71) of patients had CD4 cell count of ≤50 cells/µL signifying the stage of severe
immunosuppression while <4% of patients had CD4 cell count of >200 cells/µL (Table 1).

HAART REGIMEN USED AS FIRST LINE
Stavudine/Lamivudine/Nevirapine was prescribed as first line regimen in 87.10% of patients
while 12.90% had Stavudine/Lamivudine/Efavirenz as first line (Table 2). Other HAART
regimen

introduced

during

the

course

of

patients’

management

were

Zidovudine/Lamivudine/Efavirenz and Abacavir/Zidovudine/Lamivudine.

CO-INFECTION AND CO-MORBIDITIES REVIEWED.
Candidiasis (11.30%), malarial (35.48%), pulmonary tuberculosis (13%), upper respiratory
tract infections (14.52%) and others (14.52%) were the concurrent infections with HIV while
hypertension (19.35%) was the only co-morbidity recorded (Table 3)

CONCOMITANT DRUGS PRESCRIBED
Concomitant drugs prescribed with ARVs, included Antibacterials (Amoxicillin/Clavunalate
16.13%, Ciprofloxacin 12.90% and others 24.19%), Analgesics (paracetamol 17.74%,
NSAIDS 8.06%, tramadol 9.68%), Antimalarials (Artesunate/SP 16.13%, chloroquine 8.06%,
chloroquine/SP

14.52%,

others

21%),

chlorphenamine
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37.10%,

antihypertensives

(Amiloride/HCT 17.74%, captopril 19.35%, methyldopa 11.29%, Nifedipine 9.68%, others
14.52%), metronidazole 19.35%, Bromazepam 11.29%, Fluconazole 9.68%, micronutrients
and multivitamins (Heamatinics 100%, Neurovite forte 12.90%, pyridoxine 12.90%) and
other drugs 66.13% (Table 4).

DRUG INTERACTIONS BETWEEN CONCURRENT DRUGS AND ARVS
There were the possibilities of drug-drug interactions between the following drugs.
Fluconazole/nevirapine (9.68%), rifampicin/nevirapine (1.61%), isoniazid/stavudine (13%)
and cotrimoxazole/lamivudine (100%). Table 5.

DOCUMENTED DRUG ADVERSE EFFECTS
The recorded adverse effects include pain (19.35%), diarrhoea (14.52%), weakness/fatigue
(4.84%), hallucinations (1.61%), Headache (4.84%), Insomnia (11.29%), itching (20.97%),
paraesthesia (9.68%), peripheral neuropathy (3.23%), rash (16.13%), Stevens Johnson
syndrome (1.61%) and change in taste perception (1.61%). Table 6.

Change in patients cd4 counts 6-12 months after initiation of HAART.
Out of the 62 patients studied, 21 patients (33.87%) did not repeat CD4 count test 6-12
months after initiation of HAART due to financial incapacitation of patients, 5 patients
(8.07%) defaulted while a patient (1.61%) was referred. 35 patients (56.45%) who performed
CD4 tests during follow-up visits after a mean period of 9.07 months have their data given in
Table 7. The analysis of the CD4 count showed that all except 6 patients numbered 3, 4, 7,
11, 18 and 28 (17.14%), had an increase of >50 cells/µL. Mean CD4 cell count of the patients
increased from 98.40 ± 66.85 cells/µL (median 104 cells/µL) at baseline to 267.60 ± 141
cells/µL (median 267 cells/µL) (p<0.01).

DISCUSSION
Out of sixty two (62) patients studied, 30.65% were males while 69.35% were females giving
a male to female ratio of 1 to 2.3. This ratio seems to be in line with findings of a research on
HIV/AIDS conducted in Ile-Ife Nigeria which reported a male to female ratio of 1 to 1.4
(Akinola et al., 2004) .This is also in agreement with studies that reported that women are
more susceptible to HIV-1 infection due to hormonal changes as a result of use of hormonal
contraceptives, vaginal microbial ecology and physiology and a higher prevalence of sexually
transmitted diseases (Lavreys et al., 2004).
A majority of patients studied in the present work (72.59%) were within the age bracket of
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21-40 years with a mean age of 35.20 ± 10.50 years. This finding corroborates with the
Federal Ministry of Health year 2001 National HIV/Syphilis sentinel survey (FMoHN, 2001)
which reported that over 70% of adults infected with HIV/AIDS in Nigeria falls within the
age bracket of 15-34 years. This is the age range that corresponds considerably to years of
sexual activity and economic productivity. The implication of this will be a growing number
of AIDS orphans and a strong economic burden which could cripple the workforce of the
country.
According to the patient categorization based on 2006 WHO clinical staging system, the
study showed that 66.14% of the patients belonged to stage III or IV. This implies that
majority of the HIV patients did not promptly seek medical treatment until the disease had
reached an advanced stage. This might be as a result of either ignorance of availability of free
antiretroviral drugs or the fear of social discrimination and isolation which were usually
meted to people identified to be living with HIV/AIDS. This finding is similar to Ghana HIV
cohort study in which 78% of patients had disease classified as WHO stage III or IV (Collini
et al., 2009).
The present work also shows that patients studied had a baseline CD4 count ranging from 4
to 278 cells/µL. About thirty five percent (35.71%) of patients had CD4 count of ≤50
cells/µL signifying the stage of severe immunosuppression. This finding is in line with
research conducted in New Delhi, India where CD4 count of <50 cells/µL was seen in 18.6%
of patients studied (Guatam et al., 2008). All the patients studied were considered qualified
for antiretroviral therapy based on their baseline CD4 count values and WHO clinical stage
which is in line with the national guidelines on the use of antiretroviral drugs.
Concerning pharmacotherapy, 87.10% of the patients were prescribed D4T/3TC/NEV as
HAART first line regimen while the remaining 12.90% of patients who had concurrent TB
infection were prescribed a combination of D4T/3TC/EFV as HAART first line regimen in
accordance with the national guidelines. A patient had his regimen (EFV/D4T/3TC) changed
to EFV/AZT/3TC due to severe peripheral neuropathy caused by stavudine while another
patient was switched from NEV/D4T/3TC to all NRTIs regimen comprising of
ABC/AZT/3TC because of resistance and non-availability of protease inhibitor-based second
line regimen. However, this combination was inferior virologically to an efavirenz-based
regimen and was generally not recommended (Gulick et al., 2004).
As regards concurrent infections and co-morbidity recorded with the retroviral disease only
tuberculosis (TB) required special consideration as to the choice of NNRTI to be selected as
component of HAART and therefore, efavirenz was given priority over nevirapine because it
can be co-administer with rifampicin which is a basic component of anti TB drug regimen
7

unlike nevirapine which interact significantly with rifampicin which might result in HAART
therapeutic failure. However, a patient who had her efavirenz changed to nevirapine three (3)
months into therapy because of drug-induced hallucinations defaulted before she could be
evaluated.
In the present study, different drugs were prescribed concurrently with ARVs to manage
patients. Cotrimoxazole was prescribed for all the patients as prophylaxis against
opportunistic infections in conformity with WHO guidelines which recommends the use of
cotrimoxazole in all HIV infected patients irrespective of the CD4 count (WHO, 2006). Over
50% of patients who were infected with malaria were treated with combination of
antimalarials that contains sulfadoxine/pyrimethamine (SP). This was at variance to WHO
recommendations that HIV patients infected with malaria and are already on cotrimoxazole
prophylaxis should be treated with antimalarials other than SP because of the problem of
cross-resistance (WHO, 2006). This work also revealed that patients with hypertension were
prescribed an average of three antihypertensives. Combination of these drugs with the
HAART regimen and opportunistic infection prophylactic drugs might result in nonadherence due to high pill burden and barrage of adverse effects (Haider et al., 2009).
A thorough review of patients’ medication profile showed that nevirapine could have
interacted with fluconazole in 9.68% of the patients thereby resulting in an increase risk of
hepatotoxicity. Interaction between stavudine and isoniazid can result in aggravation of
peripheral neuropathy as this combination was seen in 13% of the patients, although 25mg
daily dose of pyridoxine was prescribed to alleviate the condition. The interaction problem
that could have resulted from combination of lamivudine and cotrimoxazole was mitigated
with the adjustment of cotrimoxazole dose to 960 mg daily.
Drug adverse effects constitute major challenge to patient’s adherence to medications and
among the most common reasons for switching or discontinuation of therapy (O’Brein et al.,
2003). In this present study, three patients had regimen switched because of adverse effects
while a female patient had her HAART regimen discontinued due to serious adverse effect
(Stevens Johnson syndrome). Generally, patients were able to tolerate their medications due
to transient nature of most of the adverse effects reported.
Concerning therapeutic response to HAART as measured by change in patients’ CD4 count,
82.86% of patients recorded an increase of >50 cells/µL after 6-12 months period of therapy.
An adequate CD4 response to HAART is defined as an increase in the range of 50-150
cells/µL for first year of therapy and increases that average 50-100 cells/µL for subsequent
years until a steady state is reached (Kaufmann et al., 2003). In the present study, it could be
concluded that 82.86% therapeutic success was achieved 6-12 months after HAART.
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In this study, there was a significant difference (p<0.01) in the change in CD4 count among
male and female patients as female patients recorded higher CD4 count changes (mean CD4
count increased from 108.5 ± 59.10 cells/µL to 303.5 ±130.30 cells/µL) when compared to
their male counterparts (mean CD4 count increased from 81.31 ± 77.80 cells/µL to 206.85 ±
142.42 cells/µL) 6-12 months after initiation of HAART. This finding was in line with the
work of Thomas et al (2003) which reported greater CD4 cell count increases for women
compared to men 6 months after HAART (Giordano et al., 2003). Also in this study, there
was no significant correlation between patient’s age and change in CD4 count 6-12 months
after initiation of therapy (p> 0.05). The present finding is contrary to the findings of
Manfredi and Chiodo which reported significant correlation between patient’s age and CD4
count after one year of HAART (Manfredi and Chiodo, 2000). However, there was a
significant positive correlation (p< 0.05) between age and change in CD4 count within male
patients but there was no significant correlation (p> 0.05) between age and change in CD4
count within female patients. As regards baseline CD4 count value, there was a significant
positive correlation (p< 0.05) between baseline CD4 count value and change in patients CD4
count among patients and also within female patients but there was no significant correlation
between baseline CD4 count value and change in CD4 count within male patients (p> 0.05).
In conclusion, this study has showed that rational use of HAART in the management of
HIV/AIDS can lead to significant improvement in most patients’ immunological status and
invariably quality of life. However, full benefits of HAART can only be realized, if patients
report for treatment on time and adhere to prescribed drug therapy.

RECOMMENDATIONS
In order to curtail the spread of HIV/AIDS and to effectively manage those already infected,
the following measures are suggested;
There should be an intensification of public awareness campaign on HIV/AIDS;
-

More voluntary counseling and testing (VCT), and treatment centre should be
established, especially in the rural areas;

-

There should be a legalization against discrimination of people living with
HIV/AIDS;

-

All aspects of HIV/AIDS management including laboratory services and drugs should
be made free;

-

All the three (3) classes of antiretroviral drugs including the protease inhibitors
should be made available;

-

Adherence counseling should be given to patients before initiation of therapy and at
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every clinic visit;
-

Patients evaluation tests such as CD4 count, liver function test (LFT), plasma HIV
RNA, full blood count and basic chemical test should be performed at stated intervals;

-

Efforts should be intensified to get a permanent cure for HIV/AIDS.
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Figure1. Bar chart showing patients categorization based on clinical staging
system.
Table 1. Analysis of patient CD4 count at Baseline.
CD4 count (cells/µL)
1-50
51-100
101-150
151-200
201-250
251-300
Total

Frequency
20
10
17
7
1
1
56

Percent
35.71
17.86
30.35
12.50
1.79
1.79
100.00

Data extracted from the patients’ case notes obtained from the Medical Records department
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Table 2. HAART Regimen used as first line
Regimen
d4T/3TC/NEV
d4T/3TC/EFV
Total

Frequency
54
8
62

Percent
87.10
12.90
100.00

Data extracted from the patients’ case notes obtained from the Medical Records department
Table 3. Co-Infections and co-morbidities
Disease
Frequency
Co-Infection
Candidiasis
7
Malaria
22
Pulmonary
8
tuberculosis
Upper respiratory tract
9
infections
Others
9
Co-morbidity
Hypertension
12

reviewed.
Percent
11.30
35.48
13.00
14.52
14.52
19.35

Data extracted from the patients’ case notes obtained from the Medical Records department
TABLE 4. CONCOMITANT DRUGS PRESCRIBED
Class of Drug
Frequency of prescriptions
Antibacterials
111
Analgesics
22
Antimalarials
37
Antihistamines
23
Antihypertensives
45
Antimicrobials
12
Antifungals (oral)
6
Benzodiazepines
7
Multivitamins/ Minerals
78
Other drugs
41
Data extracted from the patients’ case notes obtained from the Medical Records department
Table 5. Possible interactions
prescribed
Drug
ARV
Fluconazole
Nevirapine
Isoniazid
Stavudine
Cotrimoxazole
Lamivudine
Rifampicin
Nevirapine

between concurrent drugs and ARVs
Frequency
6
8
62
1

Percent
9.68
13.00
100.00
1.61

Data extracted from the patients’ case notes obtained from the Medical Records department
Table 6. Documented Adverse Effects
14

Adverse Effect
Frequency
Percent
Pain
12
19.35
Diarrhoea
9
14.52
Weakness/Fatigue
3
4.84
Hallucinations
1
1.61
Headache
3
4.84
Insomnia
7
11.29
Itching
13
20.97
Paraesthesia
6
9.68
Peripheral neuropathy
2
3.23
Rash
10
16.13
Stevens Johnson Syndrome
1
1.61
Hearing loss
1
1.61
Vomiting
3
4.84
Data extracted from the patients’ case notes obtained from the Medical Records department
Table 7. Change in patient CD4 count 6-12 months after initiation of
HAART (n=35).
Patient
Age
Gender
CD4 count (cells/µL)
No
(years)
Baseline
6-12
Difference
months
1
30
F
160
499
339
2
52
M
4
119
115
3
39
F
94
133
39
4
28
M
15
18
3
5
40
M
124
269
145
6
32
F
126
424
298
7
36
F
114
139
25
8
52
F
146
334
188
9
31
F
33
119
86
10
30
F
30
269
239
11
32
M
147
182
35
12
33
F
189
510
321
13
42
M
278
482
204
14
39
M
14
206
192
15
40
M
143
267
124
16
45
F
50
145
95
17
41
M
17
264
247
18
37
M
75
41
-34
19
53
F
39
173
134
20
42
M
50
185
135
21
30
F
20
204
184
22
28
F
126
392
266
23
34
M
29
140
111
24
40
M
105
452
347
25
27
F
111
316
205
26
25
F
177
394
217
27
40
F
212
313
101
28
16
M
56
64
8
15

29
30
31
32
33
34
35

30
30
30
26
58
30
50
•
•

F
F
F
F
F
F
F

11
104
98
183
78
139
147

118
302
230
436
352
487
388

107
198
132
253
274
348
241

Abbreviations, M-male, F-female
Data extracted from the patients’ case notes obtained from the Medical Records
department
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